Does the media favor NBP or ACRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 5 mentions for I-Mab. I-Mab's average media sentiment score of 0.89 beat Aclaris Therapeutics' score of 0.59 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NBP or PHAR?

Pharming Group has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 47.27 -$46.27M -$0.36 N/A Pharming Group $376.13M 2.11 $2.85M $0.12 93.42

Does the media prefer NBP or PHAR?

In the previous week, Pharming Group had 6 more articles in the media than I-Mab. MarketBeat recorded 11 mentions for Pharming Group and 5 mentions for I-Mab. Pharming Group's average media sentiment score of 1.09 beat I-Mab's score of 0.89 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or NBP?

In the previous week, I-Mab had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for I-Mab and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat I-Mab's score of 0.89 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive I-Mab 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NBP or MNPR more profitable?

I-Mab's return on equity of 0.00% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Monopar Therapeutics N/A -13.08% -12.79%

Does the media favor NBP or MNPR?

In the previous week, I-Mab had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for I-Mab and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.04 beat I-Mab's score of 0.89 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NBP or NVCT more profitable?

I-Mab's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer NBP or NVCT?

In the previous week, I-Mab had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for I-Mab and 3 mentions for Nuvectis Pharma. I-Mab's average media sentiment score of 0.89 beat Nuvectis Pharma's score of 0.62 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

I-Mab (NBP) Competitors

$1.59 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.60 +0.01 (+0.75%)

As of 09/11/2026 07:51 PM Eastern

Compare

NBP vs. ACRS, PHAR, FDMT, MNPR, and NVCT

Should you buy I-Mab stock or one of its competitors? I-Mab's main competitors and comparable companies include Aclaris Therapeutics (ACRS), Pharming Group (PHAR), 4D Molecular Therapeutics (FDMT), Monopar Therapeutics (MNPR), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does I-Mab compare to Aclaris Therapeutics?

I-Mab (NASDAQ:NBP) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

I-Mab has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.27	-$46.27M	-$0.36	N/A
Aclaris Therapeutics	$7.83M	95.00	-$64.92M	-$0.58	N/A

I-Mab has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 5 mentions for I-Mab. I-Mab's average media sentiment score of 0.89 beat Aclaris Therapeutics' score of 0.59 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. I-Mab's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

I-Mab currently has a consensus target price of $9.00, indicating a potential upside of 466.04%. Aclaris Therapeutics has a consensus target price of $11.33, indicating a potential upside of 113.03%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

I-Mab beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.

How does I-Mab compare to Pharming Group?

I-Mab (NASDAQ:NBP) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Pharming Group had 6 more articles in the media than I-Mab. MarketBeat recorded 11 mentions for Pharming Group and 5 mentions for I-Mab. Pharming Group's average media sentiment score of 1.09 beat I-Mab's score of 0.89 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.4% of I-Mab shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 466.04%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 244.93%. Given I-Mab's higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

I-Mab has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Pharming Group has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.27	-$46.27M	-$0.36	N/A
Pharming Group	$376.13M	2.11	$2.85M	$0.12	93.42

Pharming Group has a net margin of 2.51% compared to I-Mab's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats I-Mab on 11 of the 16 factors compared between the two stocks.

How does I-Mab compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

I-Mab has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A
I-Mab	$3.89M	47.27	-$46.27M	-$0.36	N/A

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

4D Molecular Therapeutics presently has a consensus price target of $29.63, suggesting a potential upside of 124.94%. I-Mab has a consensus price target of $9.00, suggesting a potential upside of 466.04%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, I-Mab had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for I-Mab and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat I-Mab's score of 0.89 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. I-Mab's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
I-Mab	N/A	N/A	N/A

4D Molecular Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market. Comparatively, I-Mab has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

I-Mab beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks.

How does I-Mab compare to Monopar Therapeutics?

I-Mab (NASDAQ:NBP) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

I-Mab presently has a consensus target price of $9.00, suggesting a potential upside of 466.04%. Monopar Therapeutics has a consensus target price of $120.08, suggesting a potential upside of 8.91%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, I-Mab had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for I-Mab and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.04 beat I-Mab's score of 0.89 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

38.4% of I-Mab shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

I-Mab's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Monopar Therapeutics	N/A	-13.08%	-12.79%

Monopar Therapeutics has lower revenue, but higher earnings than I-Mab. Monopar Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.27	-$46.27M	-$0.36	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Summary

I-Mab beats Monopar Therapeutics on 10 of the 15 factors compared between the two stocks.

How does I-Mab compare to Nuvectis Pharma?

I-Mab (NASDAQ:NBP) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 466.04%. Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 51.10%. Given I-Mab's higher probable upside, research analysts clearly believe I-Mab is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

I-Mab has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market.

In the previous week, I-Mab had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for I-Mab and 3 mentions for Nuvectis Pharma. I-Mab's average media sentiment score of 0.89 beat Nuvectis Pharma's score of 0.62 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Nuvectis Pharma	N/A	-184.25%	-105.24%

38.4% of I-Mab shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvectis Pharma has lower revenue, but higher earnings than I-Mab. Nuvectis Pharma is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	47.27	-$46.27M	-$0.36	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

I-Mab beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$183.88M	$3.85B	$7.15B	$12.84B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-4.42	14.25	275.24	25.35
Price / Sales	47.27	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.80	15.12	10.33	6.21
Net Income	-$46.27M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-11.67%	-4.34%	-3.32%	-2.35%
1 Month Performance	-18.88%	-0.65%	-0.87%	-3.37%
1 Year Performance	N/A	40.74%	23.50%	8.81%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	2.7367 of 5 stars	$1.59 flat	$9.00 +466.0%	N/A	$183.88M	$3.89M	N/A	380	Gap Up
ACRS Aclaris Therapeutics	2.2831 of 5 stars	$5.32 -3.4%	$11.33 +113.0%	+172.8%	$769.73M	$7.83M	N/A	100
PHAR Pharming Group	4.399 of 5 stars	$11.21 +3.7%	$38.67 +244.9%	-23.6%	$764.76M	$376.13M	93.42	280	Short Interest Decrease High Trading Volume
FDMT 4D Molecular Therapeutics	3.7396 of 5 stars	$13.17 -2.4%	$29.63 +124.9%	+93.4%	$745.24M	$85.21M	N/A	120	Positive News Gap Up
MNPR Monopar Therapeutics	1.8621 of 5 stars	$110.26 +0.3%	$120.08 +8.9%	+124.0%	$738.07M	N/A	N/A	10	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. ACRS, PHAR, FDMT, MNPR, and NVCT

How does I-Mab compare to Aclaris Therapeutics?

Summary

How does I-Mab compare to Pharming Group?

Summary

How does I-Mab compare to 4D Molecular Therapeutics?

Summary

How does I-Mab compare to Monopar Therapeutics?

Summary

How does I-Mab compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. ACRS, PHAR, FDMT, MNPR, and NVCT

How does I-Mab compare to Aclaris Therapeutics?

Which has better valuation and earnings, NBP or ACRS?

Which has more risk & volatility, NBP or ACRS?

Does the media favor NBP or ACRS?

Is NBP or ACRS more profitable?

Do analysts rate NBP or ACRS?

Do institutionals & insiders believe in NBP or ACRS?

Summary

How does I-Mab compare to Pharming Group?

Does the media prefer NBP or PHAR?

Do institutionals and insiders believe in NBP or PHAR?

Do analysts prefer NBP or PHAR?

Which has more volatility and risk, NBP or PHAR?

Which has better earnings and valuation, NBP or PHAR?

Is NBP or PHAR more profitable?

Summary

How does I-Mab compare to 4D Molecular Therapeutics?

Which has stronger earnings and valuation, FDMT or NBP?

Do institutionals & insiders hold more shares of FDMT or NBP?

Do analysts prefer FDMT or NBP?

Does the media refer more to FDMT or NBP?

Is FDMT or NBP more profitable?

Which has more volatility & risk, FDMT or NBP?

Summary

How does I-Mab compare to Monopar Therapeutics?

Do analysts prefer NBP or MNPR?

Does the media favor NBP or MNPR?

Which has more volatility and risk, NBP or MNPR?

Do institutionals and insiders have more ownership in NBP or MNPR?

Is NBP or MNPR more profitable?

Which has stronger valuation and earnings, NBP or MNPR?

Summary

How does I-Mab compare to Nuvectis Pharma?

Do analysts prefer NBP or NVCT?

Which has more risk & volatility, NBP or NVCT?

Does the media prefer NBP or NVCT?

Is NBP or NVCT more profitable?

Do institutionals & insiders have more ownership in NBP or NVCT?

Which has preferable valuation and earnings, NBP or NVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools